Sarcoma  >>  sunitinib 
Welcome,         Profile    Billing    Logout  

34 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sunitinib / Generic mfg.
2012-000425-45: Effect van ochtend- of avondinname van sunitinib op de medicijnspiegels in het bloed

Ongoing
4
18
Europe
Sunitinib, Midazolam, EU/1/06/347/001-008, PL 29831/0140, Sutent, Dormicum, Sutent, Dormicum
Renal Cell Cancer, GIST, pancreatic neuroendocrine tumor Niercelcarcinoom, GIST, p-NET
 
 
INTRIGUE, NCT03673501 / 2018-001803-35: A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

Active, not recruiting
3
453
Europe, Canada, US, RoW
Ripretinib, DCC-2618, Sunitinib, Sutent
Deciphera Pharmaceuticals LLC
Gastrointestinal Stromal Tumors
09/21
12/24
NCT04409223: Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib

Terminated
3
185
RoW
Famitinib capsules, Sunitinib Capsules, Sutent
Jiangsu HengRui Medicine Co., Ltd.
Gastrointestinal Stromal Tumors
03/22
03/22
PEAK, NCT05208047: (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Recruiting
3
426
Europe, Canada, US, RoW
CGT9486 plus sunitinib, CGT9486, Sunitinib, sunitinib - Part 1b, sunitinib - Part 2
Cogent Biosciences, Inc.
Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer
07/25
09/26
INSIGHT, NCT05734105: A Study of Ripretinib Vs Sunitinib in Patients with Advanced GIST with Specific KIT Exon Mutations Who Were Previously Treated with Imatinib

Recruiting
3
54
Europe, Canada, US, RoW
Ripretinib, QINLOCK, DCC-2618, Sunitinib, Sutent
Deciphera Pharmaceuticals, LLC
GIST
02/26
12/27
NCT00265798: Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate

Active, not recruiting
2
38
US
Sorafenib Tosylate, BAY 43-9006 Tosylate, BAY 54 9085, BAY 54-9085, BAY 549085, BAY-54-9085, BAY549085, Nexavar, sorafenib
National Cancer Institute (NCI)
Gastrointestinal Stromal Tumor
02/10
03/25
NCT06390826: Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

Active, not recruiting
2
35
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Sunitinib
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
03/25
03/25
2008-000756-27: Activity of sunitinib in esophageal cancer, melanoma and sarcoma.

Ongoing
2
96
Europe
Sutent, Sutent
UZ Brussel
Patients with advanced esophageal cancer, melanoma and sarcoma.
 
 
2019-001316-38: A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Et lægemiddelforsøg af en individualiseret behandlingsstrategi til patienter med undertypen non-clear celle nyrekræft, som har spredt sig

Not yet recruiting
2
30
Europe
Capsule, hard, Film-coated tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tafinlar, Tarceva, Keytruda, Mekinist, Alecensa, Lynparza, Kadcyla, Cabometyx, Xalkori, Ibrance, Tagrisso, Glivec, Sutent, Opdivo
Department of Oncology, Herlev University Hospital, Region Hovedstaden, Roche Denmark
Patients with metastatic non-clear cell or 100% sarcomatoid renal cell carcinoma referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med metastatisk non-clear cell eller 100% sarkomatoid nyrekræft, som henvises med henblik på første linje behandling på onkologisk afdeling, Herlev Hospital, Patients with metastatic kidney cancer with the subtype non-clear cell or 100% sarcomatoid referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med undertypen non-clear cell eller 100% sarkomatoid nyrekræft, som har spredt sig og henvises for at påbegynde den første medicinske kræftbehandling på onkologisk afdeling, Herlev Hospital, Diseases [C] - Cancer [C04]
 
 
2018-004332-30: Study that evaluating the efficacy of lenvatinib in patients with locally advanced GIST after failure of imatinib and sunitinib Etude évaluant l’efficacité du Lenvatinib chez des patients présentant un GIST localement avancé après échec de l’imatinib et du sunitinib

Not yet recruiting
2
74
Europe
E7080, Capsule, Lenvima
Centre Léon Bérard, EISAI SAS
Patients with locally advanced or metastatic GIST after failure of imatinib and sunitinib (either on 3rd line treatment or beyond a 3rd line with regorafenib) Patients avec un GIST métastatique ou localement avancé, après échec du traitement par imatinib et sunitinib (en 3ème ligne de traitement ou au-delà d’une 3ème ligne par regorafenib), Patients with metastatic GIST Patients présentant un GIST métastatique, Diseases [C] - Cancer [C04]
 
 
ChiCTR1800020407: Efficacy and safety of apapitatin mesylate in the treatment of metastatic gastrointestinal stromal tumor (GIST) with failed imatinib mesylate or sunitinib

Recruiting
2
30
 
Apatinib 500mg qd
West China Hospital, Sichuan University; West China Hospital, Sichuan University, CSCO Funding
Gastrointestinal stromal tumor
 
 
LENVAGIST, NCT04193553: Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure

Completed
2
77
Europe
Lenvatinib, Placebo, Best supportive care
Centre Leon Berard
Gastro Intestinal Stromal Tumour
01/24
04/24
NCT03944304: Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.

Recruiting
2
40
RoW
Paclitaxel
Asan Medical Center
Gastrointestinal Stromal Tumors
11/25
11/25
NCT01391962: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Active, not recruiting
2
34
US
Cediranib, AZD2171 maleate, Recentin, AXD2171, Sunitinib, Sutent, SU11248, SU011248, Prochlorperazine, Compro, Promethazine, Phenadoz, Phenergan, Promethegan, Benzodiazepine, Valium, Diazepam, Estazolam, ProSom, Flurazepam, Dalmane, Lorazepam, Ativan, Filgrastim, Neupogen, Sargramostim, Leukine, Lomotil, Diphenoxylate hydrochloride (HCL)/atropine, Loperamide, Imodium, Diamode, Anti-Diarrheal (loperamide), Vitamin B6, Pyridoxine, Aquaphor, Acetaminophen, Tylenol, Ofirmev, FeverAll, Levothyroxine, Synthroid, Tirosint, Unithroid, Warfarin, Coumadin
National Cancer Institute (NCI)
Sarcoma, Alveolar Soft Part
11/23
03/25
NCT06208748: SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

Recruiting
2
40
US
Bezuclastinib in combination with sunitinib
Sarcoma Alliance for Research through Collaboration, Cogent Biosciences, Inc., Dana-Farber Cancer Institute, The Life Raft Group
Gastrointestinal Stromal Tumors, GIST
06/26
06/27
NCT06326346: GIST Oral Paclitaxel(Liporaxel)

Not yet recruiting
2
28
RoW
Liporaxel
Asan Medical Center
Gastrointestinal Stromal Tumors
03/27
03/27
CABOSUN II, NCT03541902: Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Checkmark Results from CABOSUN study
Oct 2018 - Oct 2018: Results from CABOSUN study
Active, not recruiting
2
32
US
Cabozantinib, Sunitinib Malate, SU011248, SU11248, sunitinib, Sutent
M.D. Anderson Cancer Center, Exelixis, National Cancer Institute (NCI)
Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
07/25
07/25
NCT05905887: Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

Recruiting
2
48
RoW
Rivoceranib Mesylate, Paclitaxel
Asan Medical Center
Gastrointestinal Stromal Tumors
08/26
12/26
NCT05366816: ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

Recruiting
2
48
US
Sunitinib, Sutent, SU11248, Regorafenib, Stivarga, Regonix, BAY 73-4506
University of Miami
Gastrointestinal Stromal Tumors
12/26
12/28
ACTRN12608000474358: A phase IB/II study of sunitinib in combination with neoadjuvant radiation in patients with resectable soft tissue sarcoma

Recruiting
1/2
26
 
Peter MacCallum Cancer Centre, Pfizer Inc.
Soft tissue sarcoma
 
 
NCT05160168: A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Terminated
1/2
32
US
THE-630
Theseus Pharmaceuticals
Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasm, Digestive System Disease, Gastrointestinal Diseases
02/24
02/24
ImmunoSarc, NCT03277924 / 2016-004040-10: Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Completed
1/2
197
Europe
Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Sutent, Nivolumab 100 MG/10 ML [Opdivo], Opdivo, Epirubicin, Ifosfamide, Doxorubicin, Dacarbazine, Cisplatin, Methotrexate
Grupo Espanol de Investigacion en Sarcomas
Soft Tissue Sarcoma, Bone Sarcoma
06/24
06/24
ChiCTR-IIR-16009460: Bioequivalence test of Sunitinib Malate Capsules in Chinese healthy subjects

Recruiting
1
48
 
Sunitinib Malate Capsules produced by CSPC Ouyi Pharmaceutical Co., Ltd ;Sunitinib Malate Capsules produced by Pfizer Italia S.r.l.
The first hospital of Jilin university; Level of the institution：, CSPC Ouyi Pharmaceutical Co., Ltd
Gastrointestinal Stromal Tumors、renal cell carcinoma
 
 
NCT05800106: A Bioequivalence Study of Sunitinib Malate Capsules.

Completed
1
24
RoW
Sunitinib malate capsules generic product, Sunitinib malate capsules reference product
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gastrointestinal Stromal Tumors, Renal Cell Carcinoma, Pancreatic Neuroendocrine Tumor
01/19
01/19
NCT04006769: Entacapone Combination With Imatinib for Treatment of GIST

Completed
1
5
RoW
Entacapone, Comtan, Comtess, Imatinib Mesylate, Gleevec
Xiangya Hospital of Central South University
Gastrointestinal Stromal Tumor, Malignant
08/22
08/22
NCT03900793: Losartan + Sunitinib in Treatment of Osteosarcoma

Recruiting
1
41
US
Losartan, Sunitinib, Sunitinib Malate
University of Colorado, Denver
Osteosarcoma
08/26
02/27
CHAPTER-GIST-101, NCT05245968: A Study of Pimitespib in Combination With Imatinib in Patients With GIST

Recruiting
1
78
Japan, RoW
Pimitespib, TAS-116, Imatinib, Sunitinib
Taiho Pharmaceutical Co., Ltd.
Gastrointestinal Stromal Tumors
12/25
12/25
StrateGIST 1, NCT05489237: A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: ]

Recruiting
1
240
Europe, US
IDRX-42
IDRx, Inc.
Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer
04/26
09/26
NCT01646593: Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy

No Longer Available
N/A
US
Regorafenib (BAY73-4506)
Bayer
Gastrointestinal Stromal Tumors
 
 
NCT01689376: Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)

No Longer Available
N/A
RoW
Regorafenib (BAY73-4506)
Bayer
Gastrointestinal Stromal Tumors
 
 
ChiCTR2000029913: Role of surgery in patients with focally progressive GISTs after imatinib treatment: a prospective, multicenter, registration study

Recruiting
N/A
122
 
Surgery + Imatinib400mg/d ;imatinib 600mg/d or sunitinib 37.5mg/d
Zhongshan Hospital affiliated to Fudan University; Zhongshan hospital affiliated to fudan university, National natural science foundation of China (81773080)
Gastrointestinal stromal tumor
 
 
NCT05381753: Safety and Efficacy of Avapritinib in Chinese Patients with Gastrointestinal Stromal Tumor (GIST) in the Real World

Active, not recruiting
N/A
60
RoW
Avapritinib, Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )
CStone Pharmaceuticals
Gastrointestinal Stromal Tumors
05/25
10/25
NCT05751733: Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Recruiting
N/A
258
RoW
Apatinib Mesylate, Sunitinib, Imatinib dosage, Dasatinib, Reveratinib
Xiangya Hospital of Central South University, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Gastrointestinal Stromal Tumors
01/26
01/27
TARGETMONITO, NCT05443087: TARGETed Therapy Drug MONITOring in DIGestive Oncology

Recruiting
N/A
330
Europe
Blood sampling to build population pharmacokinetics model
UNICANCER
Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma, GIST, Neuroendocrine Tumors
08/26
06/27

Download Options